Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7 alpha-hydroxylase gene causes severe neonatal liver disease

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI2962

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Clinical Investigation

Publisher Rights Statement:
© 1998 The American Society for Clinical Investigation, Inc.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Identification of a New Inborn Error in Bile Acid Synthesis: Mutation of the Oxysterol 7α-Hydroxylase Gene Causes Severe Neonatal Liver Disease

Kenneth D.R. Setchell,* Margrit Schwarz,† Nancy C. O’Connell,* Erik G. Lund,‡ Daphne L. Davis,§ Richard Lathe,§ Henry R. Thompson,‖ R. Welsey Tyson,‖ Ronald J. Sokol,‖ and David W. Russell‡

*Clinical Mass Spectrometry Center, Department of Pediatrics, Children’s Hospital Medical Center, Cincinnati, Ohio 45229; †Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75235; ‡Centre for Genome Research, University of Edinburgh, Edinburgh, Scotland; and Pediatric Liver Center, Section of Pediatric Gastroenterology, Hepatology and Nutrition, The Children’s Hospital, University of Colorado Health Sciences Center, Denver, Colorado 80218

Abstract

We describe a metabolic defect in bile acid synthesis involving a deficiency in 7α-hydroxylation due to a mutation in the gene for the microsomal oxysterol 7α-hydroxylase enzyme, active in the acidic pathway for bile acid synthesis. The defect, identified in a 10-wk-old boy presenting with severe cholestasis, cirrhosis, and liver synthetic failure, was established by fast atom bombardment ionization-mass spectrometry, which revealed elevated urinary bile acid excretion, a mass spectrum with intense ions at m/z 453 and m/z 510 corresponding to sulfate and glycosulfate conjugates of unsaturated monohydroxy-cholenoic acids, and an absence of primary bile acids. Gas chromatography-mass spectrometric analysis confirmed the major products of hepatic synthesis to be 3β-hydroxy-5-cholenoic and 3β-hydroxy-5-cholestenolic acids, which accounted for 96% of the total serum bile acids. Levels of 27-hydroxycholesterol were >4,500 times normal. The biochemical findings were consistent with a deficiency in 7α-hydroxylation, leading to the accumulation of hepatotoxic unsaturated monohydroxy bile acids. Hepatic microsomal oxysterol 7α-hydroxylase activity was undetectable in the patient. Gene analysis revealed a cytosine to thymidine transition mutation in exon 5 that converts an arginine codon at position 388 to a stop codon. The truncated protein was inactive when expressed in 293 cells. These findings indicate the quantitative importance of the acidic pathway in early life in humans and define a further inborn error in bile acid synthesis as a metabolic cause of severe cholestatic liver disease. (J. Clin. Invest. 1998. 102: 1690–1703.) Key words: cholestasis • mass spectrometry • genetics • cholesterol metabolism

Introduction

Inborn errors in bile acid synthesis are now a recognized category of metabolic liver disease (1, 2). Specific defects have been identified in the enzymes catalyzing reactions responsible for changes to the steroid nucleus (3, 4) and side chain (5–9) of cholesterol and its intermediates in the pathway leading to the formation of cholic and chenodeoxycholic acids (10). These familial conditions are clinically manifest as syndromes of progressive cholestatic liver disease, neurological disease, and fat-soluble vitamin malabsorption (1, 2). Early diagnosis is important because patients with these disorders can be successfully treated by oral administration of cholic acid; normalization in serum liver enzymes and bilirubin and resolution of the histologic lesion are consistent responses to bile acid therapy (1, 2, 11, 12), and the need for liver transplantation in most cases can be circumvented.

Recognition of defects in bile acid synthesis has relied upon mass spectrometric analysis of the urine and serum to establish an absence or marked reduction in synthesis of the normal primary bile acids, cholic and chenodeoxycholic acids, concomitant with the presence of excessive amounts of atypical bile acids and sterols that are synthesized as a consequence of the enzyme deficiency (13). There has been relatively little success in understanding the genetic basis and molecular biology of these disorders, because with few exceptions the genes responsible for most of these enzymes have yet to be identified, sequenced, and cloned (10).

The synthesis of primary bile acids from cholesterol occurs via two pathways: the classical neutral pathway involving cholesterol 7α-hydroxylase and the acidic pathway, which uses a distinct microsomal oxysterol 7α-hydroxylase (14–20). The expression of the oxysterol 7α-hydroxylase, and hence acidic pathway, is developmentally regulated in mice (21, 22). When active, this pathway partially compensates for the neutral pathway in animals lacking the cholesterol 7α-hydroxylase gene (21), a finding that indicates the quantitative importance of the acidic pathway for bile acid synthesis. The quantitative contribution of these two pathways to total bile acid synthesis has also been measured in the rat (20) and the results reinforce the view that the acidic pathway, at least in rodents, is a major pathway for bile acid synthesis in the face of reduced cholesterol 7α-hydroxylase activity.

We now describe for the first time in a human a metabolic defect in bile acid synthesis involving a deficiency in 7α-hydroxylation that represents a further cause of severe neonatal cholestatic liver disease. The biochemical presentation of this new inborn error features almost exclusively the formation of highly cholestatic and hepatotoxic monohydroxy-bile acids with a 3β-hydroxy-Δ5 ring structure. Molecular studies establish this defect to be due to mutation of the oxysterol 7α-hydrox-
ylose gene (symbol \textit{CYP7B1}). These findings highlight the qualitative importance of the acidic pathway for bile acid synthesis in early human life.

**Methods**

**Clinical history of patient JC**

The patient was a Hispanic male infant born at term after an uneventful pregnancy by a vaginal delivery with a birth weight of 7 lb. 12 oz. (3.52 kg). The patient’s parents were first cousins, both from the same small village in Mexico. This was the second pregnancy; the first resulted in a healthy male infant who was 2.5 yr of age at the time the proband presented. The patient developed jaundice at 6 d of age (total serum bilirubin 18.6 mg/dl), which resolved with phototherapy. During week 6 of life he intermittently passed acholic stools; jaundice returned at 8 wk of age. At 10 wk of age, bright red blood was passed per rectum and a spontaneous episode of epistaxis occurred. The patient was then referred to the Children’s Hospital in Denver for evaluation. On physical examination, the patient was alert and icteric with height and weight between the 25th and 50th percentiles. A right sceral hemorrhage was present and nares were crusted with blood, but not actively bleeding. There were no dysmorphic features or cardiac murmur, and neurological examination was normal. The liver was firm and 3 cm below the right costal margin and the spleen tip was palpable. Ascites, spider hemangiomata, bruising, and edema were absent.

Initial laboratory studies revealed serum AST 440 IU/liter (normal 20–60), ALT 160 IU/liter (normal 7–46), alkaline phosphatase 1,384 IU/liter (normal 110–460), total/direct bilirubin 8.4/4.8 mg/dl (normal <1.0), prothrombin time 41 s (normal 12.4–14.4), and blood ammonia 37 μmol/liter (normal 29–57). Serum GGT was 14 IU/liter, cholesterol was 101 mg/dl, and CBC was normal. Evaluations for viral infections, alpha-1-antitrypsin deficiency, hereditary tyrosinemia, cystic fibrosis, hypopituitarism, and iron storage disease were normal or negative. Serum α-tocopherol concentration was 5.5 μg/ml (normal 3.8–15.5), α-tocopherol: total serum lipids ratio was 1.07 (normal >0.6 mg/g), serum retinol 6.0 μg/dl (normal 19–77), and retinol binding protein was 0.7 mg/dl (normal 1.0–5.0). Abdominal ultrasonography showed a small gallbladder, no choledochal cyst, no dilatation of bile ducts, and bilateral enlarged kidneys without hydronephrosis. Hepatobiliary scintigraphy with iminodiacetic acid showed delayed hepatic clearance and no biliary excretion. Parenteral vitamin K treatment led to a substantial reduction in the prothrombin time to 19.1 s. Percutaneous liver biopsy (see Results) performed after correction of coagulopathy suggested biliary tract obstruction. The patient then underwent an exploratory laparotomy which showed an enlarged, firm, green liver, a normal gallbladder containing yellow bile, and a normal biliary system was seen on an intraoperative cholangiogram performed through the gallbladder. Urine and serum were shipped to Cincinnati for evaluation of bile acid synthetic defects.

The patient was treated with a medium chain triglyceride-containing formula, fat-soluble vitamin supplementation (pytonadione, 25-hydroxy-vitamin D, α-tocopheryl PEG-1000 succinate), and urso-deoxycholic acid (UDCA) after 49 d of cholic acid therapy with continued deterioration of hepatic synthetic function (Fig. 1). Because of poor weight gain, progressive hepatosplenomegaly, hypoalbuminemia, and coagulopathy, the patient underwent orthotopic liver transplantation from a cadaver donor at 4.5 mo of age. Immunosuppression included cyclosporine, corticosteroids, and azathioprine. Acute allograft rejection occurred on day 9 after transplant and responded to large intravenous corticosteroid bolus therapy. Neutropenia developed on day 10 and was followed by 	extit{Pseudomonas aeruginosa} sepsis and erythema gangrenosum of the buttocks on day 15. The patient responded well to intravenous antibiotic therapy and a reduction of immunosuppression; however, on day 19 he developed sudden, rapidly progressive cerebral edema and died 24 h later. Autopsy revealed disseminated lymphoproliferative disease (Epstein-Barr virus–related) in all body tissues, including brain and liver, and mild allograft rejection.

**Qualitative and quantitative bile acid analysis**

Total and individual bile acids were measured in urine, serum, bile, and liver tissue from the patient using a combination of fast atom bombardment ionization-mass spectrometry (FAB-MS) and gas chromatography-mass spectrometry (GC-MS) as described elsewhere (23–25).
Solid-phase extraction of bile acids from urine, serum, and bile. The internal standard, nordeoxycholic acid (1–10 μg), was added to samples of urine (5–10 ml), bile (100 μl), and serum (0.5–1.0 ml), and bile acids were extracted by liquid-solid extraction using reverse-phase octadecylsilane-bonded silica cartridges (Bond Elut-C18 Analytichem Inc., Harbor City, CA) (26, 27). The cartridge was washed with water, and bile acids and their conjugates were recovered from the cartridge by elution with methanol (5 ml).

Extraction of bile acids from liver tissue. A small sample of liver (150 mg) obtained from the patient at the time of liver transplantation was ground to a fine paste in distilled water (20 ml) and brought to a final concentration of 80% methanol (100 ml). The sample was sonicated for 30 min, and then refluxed for 2 h and filtered (28). The residue was resuspended in 100 ml of chloroform/methanol (1:1, vol/vol), refluxed for 1 h, and filtered. The combined extracts were taken to dryness on a rotary evaporator. The dried extract was resuspended in 80% methanol (1 ml) by sonication, and the internal standard, nordeoxycholic acid (5 μg) was added. The sample was diluted with 0.01 M acetic acid (19 ml) and passed through a column of Lipidex 1000 (bed size 4 × 1 cm; Packard Instrument Co., Groningen, The Netherlands). Aqueous acetic acid (20 ml) was passed through the gel bed, followed by distilled water (20 ml), and the combined effluent and washings were then passed through a Bond Elut-C18 cartridge and discarded. Bile acids were recovered by elution of the Lipidex 1000 column and the Bond Elut-C18 cartridge with methanol, 20 and 5 ml, respectively, and the combined extracts were taken to dryness.

Solvolyis, hydrolysis, ion-exchange chromatography, and derivatization steps. The methanolic extracts from the urine, serum, bile, and liver tissue were taken to dryness under a stream of nitrogen, and bile acid conjugates were solvolyzed (29) and enzymically hydrolyzed (30). After hydrolysis, bile acids were then extracted on a Bond Elut-C18 cartridge and the unconjugated bile acids were isolated by lipophilic anion exchange chromatography on a column (bed size 0.6 g) of diethylaminohydroxypropyl Sephadex LH-20 (Lipidex DEAP; Packard Instrument Co.) prepared in 72% ethanol and converted to the acetate form (31). Unconjugated bile acids were eluted with 0.1 mol/liter acetic acid in 72% ethanol (7 ml), and converted to volatile methyl ester-trimethylsilyl (Me-TMS) ether derivatives (32) for analysis by GC-MS operated in repetitive scanning mode.

Urinary bile acid analysis by FAB-MS. Negative ion FAB-MS spectra of bile acid conjugates excreted in urine were obtained after placing 1 μl of the methanolic extract of urine before hydrolysis of conjugates (equivalent to 20 μl of the urine) onto a drop of a glycerol/methanol (1:1, by vol) matrix spotted on a stainless steel probe. The probe was introduced into the ion source of a VG Autospec Q mass spectrometer (Fisons Instruments, Manchester, UK) and ionized by a beam of fast atoms of cesium (35 keV) fired at the target containing the sample. Negative ion mass spectra were recorded over the mass range of 50–1,000 D.

GC-MS. Bile acid Me-TMS ethers were separated on a 30 mm × 0.25 mm i.d. DB-1 capillary column using temperature programmed operation from 225 to 295°C with increments of 2°C/min, after initial and final isothermal periods of 2 and 20 min, respectively. GC-MS was performed on a VG Autospec Q mass spectrometer operated in electron ionization (70 eV) mode. Repetitive scanning was performed over the mass range of 50–800 D. The identification of a bile acid was based on its GC retention index from both the scan number and time, and ion current response at its characteristic mass (33). Bile acid concentrations in urine, serum, bile, and liver tissue were quantified by gas chromatography by comparing the peak height response with the response obtained for a known amount of the added internal standard, nordeoxycholic acid (23, 34).

Biochemical enzyme assays

Microsomal membranes were prepared from frozen human liver following a standard protocol of sequential centrifugation. Aliquots of liver tissue were Dounce-homogenized in 4 vol of ice-cold sucrose buffer (0.25 M sucrose, 1 mM EDTA, 20 mM Tris-Cl, pH 7.4, 9,000 trypsin IU/ml aprotinin, 10 μg/ml pepstatin, and 5 μM phenylmethylsulfonyl fluoride). The homogenate was centrifuged for 10 min at 600 g, the supernatant was transferred to fresh tubes and centrifuged for 15 min at 10,000 g. The supernatant from this step was centrifuged for 30 min at 130,000 g. Membrane pellets from the final centrifugation step were resuspended by homogenization in 50 mM Tris-acetate (pH 7.4), 20% (vol/vol) glycerol, 1 mM EDTA. Protein concentrations were determined using the BCA protein assay kit (Pierce, Rockford, IL).

Cholesterol 7α-hydroxylase activity was assayed in the presence of 7 nmol of [4C]cholesterol (56 mCi/mmol) in 0.5 ml containing 50 mM Tris-acetate (pH 7.4), 20% (vol/vol) glycerol, 1 mM EDTA, 2 mM dithiothreitol, 0.06% Triton X-100, 1.5 mM NADPH, and 1 mg of microsomal protein. Reactions were carried out for 30 min at 37°C, followed by extraction with methylene chloride. The organic phase was taken to dryness under a stream of nitrogen gas. Lipids were redissolved in 50 μl Folch reagent (chloroform/methanol 2:1 by vol) and subjected to thin layer chromatography in ethyl acetate/toluene (2:3 by vol). Radiolabeled products were quantified using a System 200 Imaging Scanner (Bioscan Inc., Washington, DC). For determination of oxysterol 7α-hydroxylase activity, 0.06 nmol [3H]25-hydroxycholesterol (80 Ci/mmol) was incubated with 250 μg of microsomal protein using the assay described above. Steroid 5α-reductase type 1 activity was measured under the same conditions except that [4C]testosterone (58 mCi/mmol, final concentration 14 μM) was used as a substrate and the silica gel plates were developed in a solvent system containing chloroform/ethyl acetate (3:1 by vol). The detection limits for these enzymatic activities were 0.05–0.25 pmol/min/mg cell protein for oxysterol 7α-hydroxylase and steroid 5α-reductase and 0.5–2.0 pmol/min/mg cell protein for cholesterol 7α-hydroxylase.

Genetic analysis
cDNA and genomic clones encoding the human oxysterol 7α-hydroxylase were isolated by hybridization screening. The exon/intron structure of the gene was deduced by DNA sequence analysis and comparison to the cDNA sequence. Chromosomal localizations of the oxysterol 7α-hydroxylase and cholesterol 7α-hydroxylase genes were performed using the Stanford G3 panel of radiation hybrid DNAs (Research Genetics, Huntsville, AL) and PCR. A mutation in the oxysterol 7α-hydroxylase gene was identified by amplification of individual exons followed by DNA sequence analysis. The DNA sequence of the oligonucleotide primers and the thermocycler programs used to amplify exons are available upon request (D.W. Russell).

cDNA expression

 Cultured monolayers of human embryonic 293 cells or Chinese hamster ovary cells were transfected using an MBS kit (Stratagene, La Jolla, CA). Oxysterol 7α-hydroxylase enzyme activity was measured 24 h after transfection by the addition of 0.2 mM [3H]25-hydroxycholesterol to the culture media (22). After the indicated times of incubation, sterols were extracted from the media and analyzed by thin layer chromatography on silica plates. Activity was quantified by phosphorimaging. Experiments using 293 cells were carried out in the presence of 50 mM nafimidone to inhibit an endogenous oxysterol 7α-hydroxylase enzyme activity (22). Oxysterol 7α-hydroxylase protein levels were estimated by immunoblotting as described elsewhere (22). Site-directed mutagenesis was performed using PCR. All modified cDNAs were subjected to DNA sequence analysis to confirm the absence of spurious mutations.

Results

Pathology

The initial liver biopsy (day 75 of life) showed a marked increase in portal connective tissue with bridging fibrosis and probable cirrhosis (Fig. 2A). There was mild portal inflammation mixed with residual extramedullary hematopoiesis, canicular and bile duct bile plugging, and moderate lobular disarray with giant cell transformation (Fig. 2B). Prominent bile duct

1692 Setchell et al.
proliferation was also noted suggesting an obstructive etiology (Fig. 2 C). No hepatocyte drop out, viral cytopathic changes, pseudoacinar change, evidence of alpha-1-antitrypsin disease, or obvious steatosis was seen.

At time of laparotomy (day 77 of life), a wedge liver biopsy was performed and showed findings identical to the needle biopsy; cirrhosis was confirmed with regenerative nodules seen. Ultrastructural evaluation showed enlarged and often multinucleated hepatocytes containing cytoplasmic bile. Canalicular bile did not have the appearance of that seen in Byler’s disease. The mitochondria were normal in appearance and peroxisomes appeared increased in number but no structural abnormalities were identified. No metabolic storage product or viral particles were seen.

The explanted liver (day 137 of life) showed identical findings although there appeared to be hepatocytic damage due to the accumulating bile with occasional necrotic hepatocytes and patchy chronic inflammation seen (Fig. 2 D). Other than bile duct proliferation and bile plugging, the ducts appeared histologically normal, as did the gallbladder.

The posttransplant liver biopsy (day 149 of life) showed changes of moderate acute rejection with portal expansion by mononuclear inflammatory cells with bile duct involvement and portal and central vein endothelitis. No bile plugging, cholestasis, or hepatocyte drop out was seen. Subsequent liver biopsy (day 151 of life) showed resolution of findings of rejection. After the onset of sepsis, a bone marrow biopsy was done to evaluate pancytopenia and showed left-shifted maturation but no evidence of significant hemophagocytosis or other abnormalities was seen.

Figure 2. (A) Needle biopsy obtained at day 75 of life showing extensive portal fibrosis with nodules, and portal inflammation mixed with extramedullary hematopoiesis (trichrome, original magnification ×40). (B) Higher power view of same biopsy showing multinucleated giant cell transformation (arrowheads) and canalicular bile stasis (arrow). The portal tract inflammation and fibrosis are also demonstrated (hematoxylin and eosin, original magnification ×200). (C) Wedge biopsy of liver obtained at day 77 of life showing similar findings with bile duct proliferation (arrowheads) and portal fibrosis highlighted (trichrome, original magnification ×200). (D) Explanted liver, day 137 of life, showing regenerative nodules and extensive fibrosis (trichrome, original magnification ×100).
At autopsy (day 158) the large perineal ulcer with bacterial overgrowth was seen and felt to be the source of sepsis. There was third space fluid accumulation and an extensive lymphohistiocytic proliferative process involving the bone marrow, spleen, epicardium, meninges, and other soft tissues. The histology was that of Epstein-Barr virus--induced lymphoproliferative disease, and was confirmed by Eber in situ hybridization and PCR amplification. There was renomegaly with the kidneys weighing ~ 2.5 times the expected weight and grossly and histologically showed medullary cysts of varying sizes. This was the only organ system involved (other than the native liver) that may be related to the enzyme defect identified. No other developmental defects were seen.

Biochemical identification of an inborn error in bile acid synthesis

Urinary bile acid analysis. The negative ion mass spectrum of the urine from patient JC revealed a series of intense ions in the mass range corresponding to bile acids and their conjugates (m/z 350–700) and consistent with a severe cholestatic condition (Fig. 3). The major ions at m/z 453 and 510 were consistent with the pseudomolecular ions ([M–H]−) for the sulfate and glycosulfate conjugates, respectively, of monohydroxy-cholenoates (C24 bile acids). The ion at m/z 480 represents a corresponding taurine conjugate. Several other ions of unknown origin were also present. None of these ions are observed in mass spectra from the urine of normal infants of similar age, which typically show mainly ions derived from the glycerol matrix (m/z 367, 459, 551, and 643) (Fig. 3, top). Subsequent analysis of the urine from both parents by FAB-MS was unrevealing; none of the major ions observed in the mass spectrum of the patient’s urine were present in the mass spectra of the parents’ urine (data not shown), which were indistinguishable from normal adult urine.

GC-MS analysis of the Me-TMS ether derivatives of bile acids isolated after solvolysis and hydrolysis of the urine sample (Fig. 4) revealed one major compound having a retention index of 32.00 methylene units (MU). The retention index and electron ionization (70 eV) mass spectrum of this compound (Fig. 5) were found to be identical to that of the Me-TMS ether of the authentic monohydroxy bile acid, 3β-hydroxy-5-cholenoic acid (33, 35–37). The molecular ion was m/z 460, and consistent with a monohydroxy-unsaturated C24 bile acid. Prominent ions at m/z 404 [M-56], m/z 331 [M-129], the base peak, and m/z 129 are all induced by the presence of a C-5,C-6 double bond in the steroid nucleus. The 129-D fragment consists

Figure 3. The negative ion FAB-MS mass spectrum (middle) of the urine sample from a 10-wk-old patient (JC) diagnosed with oxysterol 7α-hydroxylase deficiency is compared with the corresponding mass spectrum from a normal infant of similar age (top). The mass spectrum of the urine from the patient after orthotopic liver transplantation (OLT) is shown in the bottom panel. Ions corresponding to the sulfate and glycosulfate conjugates of the monohydroxylated bile acid, 3β-hydroxy-5-cholenoic acid (m/z 453 and m/z 510, respectively), are the signature metabolites for this inborn error in bile acid synthesis. The ion m/z 514 corresponds to taurine-conjugated trihydroxycholanoic acid due to the presence of the primary bile acid, cholic acid. This sample was obtained immediately after transplantation and reflects synthesis of cholic acid by the new liver and/or the washout of cholic acid that was administered to the patient in the period leading up to orthotopic liver transplantation.
of C-1 to C-3 and 3-OTMS, while the 56-D loss involves the same carbon atoms but lacking the C-3-OTMS group. The ion at m/z 370 [M-90] is formed from the loss of the trimethylsilanol group at C-3 from the molecular ion, while the ion at m/z 255 arises from side chain cleavage (M-[90-115]). The urinary concentration of 3β-hydroxy-5-cholenoic acid was 14.0 μmol/liter and this bile acid accounted for 77.6% of the total bile acids excreted in urine (Table I). Only trace amounts of cholic acid and chenodeoxycholic acids were identified in the urine. Additionally, there was no evidence for tetrahydroxylated bile acids that are typically excreted by normal neonates.

**Serum bile acid analysis.** The GC-MS total ion current chromatogram of the Me-TMS ether derivatives of bile acids isolated from the serum of the patient was remarkably similar to that of the urinary profile (Fig. 4). Two prominent peaks were present, the major one having a retention index of 32.00 MU and an electron ionization-mass spectrum that was identical to 3β-hydroxy-5-cholenoic acid, the major urinary bile acid. An additional compound having a retention index of 34.45 MU gave an electron ionization (70 eV) mass spectrum with a fragmentation pattern that had many of the features of 3β-hydroxy-5-cholenoic acid; however, the masses of many of the ions were higher by 42 D, suggesting the addition of [-CH2-CH2-CH2] to the side chain, and consistent with the difference in mass between a C24 and a corresponding C27 bile acid structure. The molecular ion was at m/z 502 and the loss of a single trimethylsilanol function, accounting for the ion at m/z 412, confirmed a monohydroxy bile acid. Ions at m/z 446 [M-56], m/z 373 [M-129], and m/z 129 establish the presence of a 3-trimethylsiloxy-D5 structure. A C8 side chain is evi-

---

**Table I. Bile Acid Concentrations (μmol/liter or nmol/g) and Proportions (%; Shown in Parentheses) in Urine, Serum, and Liver Tissue from a Patient with an Oxysterol 7a-Hydroxylase Deficiency at Baseline, during Cholic Acid Therapy, and after Transplant, and in His Parents**

<table>
<thead>
<tr>
<th></th>
<th>3β-OH-Δ5-C24</th>
<th>3β-OH-Δ5-C27</th>
<th>CDCA</th>
<th>CA</th>
<th>Others</th>
<th>Total</th>
<th>% Mono-OH</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urine (μmol/liter)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient JC:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>14.0 (76.9)</td>
<td>ND</td>
<td>0.4 (2.2)</td>
<td>1.9 (10.4)</td>
<td>1.9 (10.4)</td>
<td>18.2</td>
<td>76.9</td>
</tr>
<tr>
<td>Day 2 therapy</td>
<td>19.9 (24.8)</td>
<td>ND</td>
<td>0.2 (0.2)</td>
<td>47.8 (59.5)</td>
<td>12.6 (15.7)</td>
<td>80.4</td>
<td>24.8</td>
</tr>
<tr>
<td>Day 4 therapy</td>
<td>5.0 (7.2)</td>
<td>ND</td>
<td>0.3 (0.4)</td>
<td>54.1 (77.3)</td>
<td>10.9 (15.5)</td>
<td>70.3</td>
<td>7.1</td>
</tr>
<tr>
<td>Day 24 therapy</td>
<td>21.4 (6.6)</td>
<td>ND</td>
<td>ND</td>
<td>234.7 (72.0)</td>
<td>69.9 (21.4)</td>
<td>326.0</td>
<td>6.6</td>
</tr>
<tr>
<td>Day 45 therapy</td>
<td>23.9 (12.4)</td>
<td>ND</td>
<td>ND</td>
<td>152.9 (79.4)</td>
<td>15.9 (8.3)</td>
<td>192.7</td>
<td>12.4</td>
</tr>
<tr>
<td>After transplant</td>
<td>11.1 (5.6)</td>
<td>ND</td>
<td>3.9 (1.9)</td>
<td>165.1 (82.8)</td>
<td>19.4 (9.7)</td>
<td>199.5</td>
<td>5.6</td>
</tr>
<tr>
<td>Parents:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mother</td>
<td>1.5 (14.5)</td>
<td>ND</td>
<td>0.5 (5.4)</td>
<td>0.3 (2.5)</td>
<td>7.7 (77.0)</td>
<td>10.0</td>
<td>15.0</td>
</tr>
<tr>
<td>Father</td>
<td>0.4 (5.9)</td>
<td>ND</td>
<td>0.5 (7.8)</td>
<td>0.3 (4.0)</td>
<td>5.7 (82.6)</td>
<td>6.9</td>
<td>5.8</td>
</tr>
<tr>
<td><strong>Serum (μmol/liter)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient JC:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>86.5 (72.5)</td>
<td>23.9 (20.0)</td>
<td>3.0 (2.5)</td>
<td>1.5 (1.3)</td>
<td>4.4 (3.7)</td>
<td>119.2</td>
<td>92.6</td>
</tr>
<tr>
<td>Day 2 therapy</td>
<td>97.1 (66.5)</td>
<td>20.8 (14.2)</td>
<td>2.9 (2.0)</td>
<td>21.5 (14.7)</td>
<td>3.8 (2.6)</td>
<td>146.1</td>
<td>80.7</td>
</tr>
<tr>
<td>Day 4 therapy</td>
<td>86.5 (75.0)</td>
<td>17.3 (14.8)</td>
<td>2.3 (2.0)</td>
<td>6.6 (5.6)</td>
<td>4.2 (3.6)</td>
<td>116.9</td>
<td>88.8</td>
</tr>
<tr>
<td>Day 45 therapy</td>
<td>66.0 (57.6)</td>
<td>4.2 (3.7)</td>
<td>2.3 (2.0)</td>
<td>40.5 (35.4)</td>
<td>1.5 (1.3)</td>
<td>114.5</td>
<td>61.3</td>
</tr>
<tr>
<td>Parents:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mother</td>
<td>ND</td>
<td>ND</td>
<td>0.8 (19.1)</td>
<td>0.3 (6.9)</td>
<td>1.9 (44.2)</td>
<td>3.0</td>
<td>0.00</td>
</tr>
<tr>
<td>Father</td>
<td>ND</td>
<td>ND</td>
<td>2.1 (43.3)</td>
<td>1.2 (23.6)</td>
<td>0.9 (18.4)</td>
<td>4.2</td>
<td>0.00</td>
</tr>
<tr>
<td><strong>Liver tissue (nmol/g)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient JC:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At transplant</td>
<td>17.3 (22.7)</td>
<td>1.5 (2.0)</td>
<td>1.9 (2.5)</td>
<td>50.1 (65.8)</td>
<td>5.3 (7.0)</td>
<td>76.1</td>
<td>24.7</td>
</tr>
</tbody>
</table>

---

**Figure 4.** Total ion current chromatograms from the GC-MS analysis of the Me-TMS derivatives isolated after solvolysis and hydrolysis of bile acids in the urine and serum from a patient (JC) with oxysterol 7a-hydroxylase deficiency. The major compounds with retention indices of 32.00 and 34.45 MU, respectively, were identified as derivatives of 3β-hydroxy-5-cholenoic and 3β-hydroxy-5-cholestenolic acids.
dent from the loss of 157 D which gives rise to the ion at m/z 255 ([M-90-157]); this represents the ABCD ring structure after loss of both the side chain and trimethylsilyloxoy group. The ion at m/z 291 represents the intact side chain and C/D rings, and is analogous to the corresponding fragment at m/z 249 seen in the mass spectrum of the C24 equivalent structure (Fig. 5). The mass spectrum and GC retention index of this serum bile acid were identical to that of 3β-hydroxy-5-cholestenoic acid (38, 39).

Total serum bile acid concentration was 114.9 µmol/liter, which was markedly elevated (upper limit of normal 3.5 µmol/liter) and consistent with a severe cholestatic condition (Table I). The 3β-hydroxy-Δ5 bile acids collectively accounted for 96% of identifiable serum bile acids. As with urine, low concentrations of cholic and chenodeoxycholic acids were present (Fig. 6).

**Biliary bile acids.** Bile obtained at the time of exploratory laparotomy was analyzed by FAB-MS. The negative ion mass spectrum showed a weak signal at m/z 453 corresponding to 3β-hydroxy-5-cholestenoic acid sulfate. There was no evidence for canalicular secretion of primary bile acids. Several prominent ions were present consistent with the pseudomolecular ions and sodium adducts of sulfate and glucuronide conjugates of neutral sterols (data not shown). However, this fraction was not analyzed by GC-MS.

**Neutral sterols in urine and serum.** The neutral sterol fractions of the baseline urine and serum samples after conversion to the trimethylsilyl ether derivatives were analyzed by GC-MS (Fig. 7). Both chromatograms show a conspicuous and major component that was identified from its electron ionization-mass spectrum (Fig. 7) and retention index (34.73 MU) as 27-hydroxycholesterol. The mass spectrum of the TMS ether showed a molecular ion at m/z 546 consistent with an unsaturated dihydroxylated C27 sterol. Ions at m/z 456 [M-90] and m/z 417 [M-129] are induced by the presence of the 5-6 double bond. The ion at m/z 129 represents a fragment consisting of the C-1 to C-3 bond and the 3-OTMS group. The mass spectrum was identical to authentic 27-hydroxycholesterol and was similar to that reported previously (40). A second prominent dihydroxy-sterol with a retention index of 34.00 MU was definitively identified as 24-hydroxycholesterol (40, 41). Its mass spectrum (Fig. 7) revealed a molecular ion at m/z 546. Ions at m/z 145, the base peak, m/z 159, and the loss of 43 D from the molecular ion (m/z 503) are explained by the fragmentation along the side chain and are induced by the presence of a 24-OTMS group. This spectrum was identical to that reported by Gustafsson and Sjovall (40). Traces of 25-hydroxycholesterol were identified in serum. Several other polyhydroxylated sterols were found in serum and urine as evidenced from their mass spectrometric fragmentation patterns but no attempt was made to identify their exact structures. While there was evidence for cholesterol, 7α-hydroxycholesterol could not be found in either the urine or serum, and there was no evidence for other 7α-hydroxylated sterols in these samples. The con-

![Figure 6](image-url) Relative proportions of bile acids in the serum and urine of a patient (JC) identified with oxysterol 7α-hydroxylase deficiency.
centrations of the major oxysterols in serum and urine are summarized in Table II.

**Effect of oral bile acid therapy with cholic acid.** Urine and serum were collected on days 2, 4, 24, and 45 during the period the patient was undergoing oral bile acid therapy with cholic acid and before liver transplantation. The GC-MS profiles were similar to those obtained from the baseline analyses but with the additional presence of the exogenous cholic acid. There was very little change in the concentrations of 3β-hydroxy-5-cholenoic and 3β-hydroxy-5-cholestenoic acids (Fig. 8), indicating that cholic acid was ineffective in downregulating endogenous bile acid synthesis by feedback inhibition (42–44).

**Liver tissue bile acids.** Bile acids were measured by GC-MS in a sample of liver tissue that was collected at the time of liver transplantation when the patient was undergoing oral bile acid therapy with cholic acid (Table I). Cholic acid was consequently the principal bile acid present, accounting for 69% of the total bile acids in the liver, and its concentration was 50 nmol/g. The concentration of 3β-hydroxy-5-cholenoic acid, the major endogenous bile acid identified in liver tissue, was 17.3

<table>
<thead>
<tr>
<th>Sterol</th>
<th>Concentration (nmol/liter)</th>
<th>Normal serum valuesa</th>
<th>Urineb</th>
</tr>
</thead>
<tbody>
<tr>
<td>7α-Hydroxycholesterol</td>
<td>Not detected</td>
<td>198±65</td>
<td>Not detected</td>
</tr>
<tr>
<td>24-Hydroxycholesterol</td>
<td>151000</td>
<td>363±15</td>
<td>3770</td>
</tr>
<tr>
<td>25-Hydroxycholesterol</td>
<td>15484</td>
<td>22±2</td>
<td>175</td>
</tr>
<tr>
<td>27-Hydroxycholesterol</td>
<td>781000</td>
<td>586±10</td>
<td>27600</td>
</tr>
<tr>
<td>Polyhydroxycholesterols</td>
<td>346700</td>
<td>—</td>
<td>5550</td>
</tr>
<tr>
<td>Total oxysterols</td>
<td>1278700</td>
<td>—</td>
<td>37095</td>
</tr>
</tbody>
</table>

*aNormal ranges for serum concentrations reported for healthy adults are taken from van Doormaal et al. (77) and Dzeletovic et al. (79) and are similar to values reported by others (39, 75, 76, 78). bDeterminations were made from a random spot urine sample.
nmol/g and it accounted for 24% of the total liver tissue bile acids. There were no other bile acids of significant concentration identified in the liver tissue.

**Bile acid metabolism after liver transplantation.** Bile and urine samples were obtained from the patient immediately after transplantation. The negative ion FAB-MS spectrum of the urine contrasts the corresponding pretransplantation spectrum of urine (Fig. 3, bottom) in that the characteristic ions at m/z 453 and 510 for the conjugates of 3β-hydroxy-5-cholenic acid were absent. Ions for the primary bile acid conjugates (m/z 514, taurocholate; m/z 498, taurochenodeoxycholic; m/z 464, glycocholate) were observed in the posttransplantation sample and reflect the elimination of the exogenous cholic acid administered up to the time of transplantation and the newly synthesized primary bile acids by the donor liver. The negative ion FAB-MS spectrum of the bile (data not shown) indicated normal canalicular secretion of the primary bile acid conjugates synthesized by the donor liver and no evidence for the atypical 3β-hydroxy-Δ5 bile acids or neutral sterols evident in fluids obtained before liver transplantation.

**Identification of an oxysterol 7α-hydroxylase defect**

**Biochemical measurement of 7α-hydroxylase activity.** Cholesterol 7α-hydroxylase enzyme activity was not detectable in normal liver tissue from infants of < 1 yr of age, or in the patient’s liver. The absence of this activity was consistent with the lack of 7α-hydroxycholesterol in the serum and urine of this individual and with earlier published studies (45). 7α-Hydroxylated 25-hydroxycholesterol was formed by membranes prepared from 1-, 2-, and 6-mo control livers (sp act = 1.4–1.8 pmol/min/mg protein), whereas there was no detectable oxysterol 7α-hydroxylase activity in the patient’s liver (Fig. 9). All specimens contained equal amounts of steroid 5α-reductase type 1 enzyme activity (Fig. 9), a marker enzyme for tissue viability.

**Molecular analyses of 7α-hydroxylase genes.** The biochemical data were consistent with a defect in either the cholesterol 7α-hydroxylase gene (symbol CYP7A1) or the oxysterol 7α-hydroxylase gene (symbol CYP7B1). To resolve this dichotomy, both genes were screened for the presence of inactivating mutations. The cholesterol 7α-hydroxylase gene has been characterized previously and oligonucleotide primers for the amplification and analysis of individual exons of the gene have been reported (46). Analysis of the six exons of CYP7A1 in the proband’s DNA by SSCP and DNA sequencing did not reveal any mutations in the coding region of the gene, suggesting that the underlying defect in this patient was not due to mutation of the cholesterol 7α-hydroxylase gene.

Oxysterol 7α-hydroxylase cDNAs encoding the rat and mouse enzymes have been reported (47); however, a cDNA for the human homologue had not been isolated, nor had the exon-intron structure of the gene or its chromosomal location been determined. To these ends, human oxysterol 7α-hydroxylase cDNAs were isolated with a two-step strategy. Initially, degenerate primers from the mouse cDNA sequence were used to isolate a fragment of the human cDNA by RT-PCR using 293 cell mRNA as a template. This fragment was then used as a probe to screen commercially available human cDNA libraries to isolate a full-length copy of the mRNA. DNA sequence analysis and conceptual translation revealed a 506-amino acid human oxysterol 7α-hydroxylase (Fig. 10). The encoded protein is 66% and 65% identical in sequence to the mouse and rat enzymes, respectively. Transfection of the human cDNA into 293 cells resulted in a threefold increase over background of oxysterol 7α-hydroxylase enzyme activity when 25-hydroxycholesterol or dehydroepiandrosterone was used as a substrate (data not shown). The 7α-hydroxylated steroids from these reactions comigrated in two different solvent systems with the products synthesized from these substrates by an expressed murine oxysterol 7α-hydroxylase whose chemical identities were confirmed (21, 22). The shared sequence identities, enzymatic properties, and gene structure and linkage (see below) indicated that the isolated human cDNA encoded a homologue of the rodent oxysterol 7α-hydroxylase.

**Figure 8.** The effect of cholic acid therapy (15 mg/kg body wt/d) on the concentrations of 3β-hydroxy-5-cholenic and 3β-hydroxy-5-cholestenoic acid in the serum and urine from a patient with an oxysterol 7α-hydroxylase deficiency. The histogram depicts the concentrations of the exogenous cholic acid administered.

**Figure 9.** Measurement of oxysterol 7α-hydroxylase and steroid 5α-reductase type 1 activity in liver membranes. Microsomal membrane proteins (250 μg) were incubated with [3H]25-hydroxycholesterol (A) or [3H]dihydrotestosterone (B) and the conversions of these substrates into [3H]cholest-5-ene-3β,7α,25-triol and [3H]dihydronecrotosterone, respectively, were determined in duplicate by thin layer chromatography. The mean activities derived from two experiments are shown. Oxysterol 7α-hydroxylase activity was detected in the control samples from individuals of age 1, 2, and 6 mo, but not in the patient’s liver (A). All samples contained similar amounts of steroid 5α-reductase type 1 activity (B).
Screening of bacteriophage lambda libraries produced the human CYP7B1 gene. Southern blotting and DNA sequence analysis of the genomic DNA and comparison to the cDNA revealed a gene composed of six exons (Fig. 10). The positions of the five introns were identical to those of the cholesterol 7α-hydroxylase gene. Both genes were positioned on the human chromosome complement by PCR analysis of radiation hybrid panel DNAs. In agreement with previous mapping data (46), CYP7A1 was localized to chromosome 8q21.13, closely linked (LOD score = 1.000) to the D8S1113 marker. Additional experiments showed that CYP7B1 was localized to chromosome 8q21.3, closely linked (LOD score = 9.7, cR value = 21.12) to the D8S1473 marker. The close linkage of the genes encoding cholesterol and oxysterol 7α-hydroxylase and their shared exon-intron structures suggest that they arose via an ancient duplication event.

To screen for mutations in the patient’s oxysterol 7α-hydroxylase gene, oligonucleotide pairs were used to amplify individual exons. Each DNA was then subjected to DNA sequence analysis. As shown in Fig. 11, the patient was homozygous for a cytosine to thymidine transition mutation in exon 5 that converted an arginine codon at position 388 to a nonsense codon (R388*). His mother (Fig. 11) and father (not shown) were heterozygous for this nonsense mutation. The R388* mutation was not detected in 16 unrelated healthy Mexican subjects and has not been found in any other control DNAs.

To confirm that the nonsense mutation abolished oxysterol 7α-hydroxylase enzyme activity, the mutation was reproduced in an expressible mouse cDNA using site-directed mutagenesis. The mouse oxysterol 7α-hydroxylase was used in these experiments due to the availability of an antibody against the murine protein (22). Transfection of the normal murine cDNA into 293 cells produced easily detectable oxysterol 7α-hydroxylase enzyme activity, whereas no activity was present in cells transfected with the cDNA containing the R388* mutation (Fig. 12). Immunoblot analysis showed that equal amounts of normal and truncated protein were present in the transfected cells (Fig. 12, inset). Similar results were obtained when the normal and mutant cDNAs were analyzed by transfection in Chinese hamster ovary cells (data not shown).

Discussion

Mammals dispose of cholesterol principally by converting it into 7α-hydroxylated bile acids that are secreted in the bile (10). The classical pathway of bile acid synthesis is initiated by

![Figure 10](image1.png)

**Figure 10.** Molecular analysis of the oxysterol 7α-hydroxylase gene. The amino acid sequence of the enzyme as deduced from translation of the cDNA is shown in a single letter code. Amino acids are numbered on the right with position 1 assigned to the initiator methionine. An asterisk marks the location of the mutation at residue 388. The accession number for the cDNA sequence is AF029403. The predicted structure of CYP7B1 is shown with exons indicated by boxes and introns by connecting lines. Exons are assigned Roman numerals and drawn to scale. The 5′- and 3′-flanking regions of the gene and the introns are not drawn to scale. Amino acids encoded by individual exons are indicated above the boxes.

![Figure 11](image2.png)

**Figure 11.** Amplification and sequencing by the dideoxyterminator method of exon 5 of the oxysterol 7α-hydroxylase gene from the genomic DNAs of the patient and his mother. A transition mutation (C→T) producing a premature termination codon (R388→Stop) is present in the heterozygous form in the mother (left) and in the homozygous form in the patient (right). The mutation occurred in a CG dinucleotide.

![Figure 12](image3.png)

**Figure 12.** Expression of the normal and mutant oxysterol 7α-hydroxylases. cDNAs encoding the normal murine cDNA or a version carrying the R388Stop mutation were inserted into a pCMV expression vector and transfected into 293 cells. The ability of the expressed proteins to convert [3H]25-hydroxycholesterol into 7α,25-dihydroxycholesterol was monitored by thin layer chromatography and expressed as a function of the incubation time. The levels of normal and mutant proteins present in the transfected cells after 1.5-h incubation were determined by immunoblotting (inset).
cholesterol 7α-hydroxylase (EC 1.14.13.17), a cytochrome P-450 enzyme of liver microsomes (48) (Fig. 13). The resultant 7α-hydroxycholesterol undergoes further hydroxylations and oxidoreduction, followed by side-chain cleavage to form the primary bile acids, cholic and chenodeoxycholic acids (10). An alternative pathway, referred to as the acidic pathway (14–20), has been described in which cholesterol is first hydroxylated in the side chain by a mitochondrial sterol 27-hydroxylase (EC 1.14.13.15) that is also localized in extrahepatic tissues including, brain (49, 50), arterial endothelium (51), and fibroblasts (52), and the product, 27-hydroxycholesterol, is further hydroxylated at the C-7α position by an oxysterol 7α-hydroxylase that resembles, but is distinct from, the cholesterol 7α-hydroxylase of the classical pathway (16, 18, 22, 53). In mice, the physiologic relevance of the alternative pathway was established by the finding that adult mice homozygous for a knockout of the cholesterol 7α-hydroxylase gene produced 7α-hydroxylated bile acids, apparently as a result of this alternative pathway (21). In the rat, under conditions of complete repression of cholesterol 7α-hydroxylation by continuous infusion of squalestatin, bile acid synthesis after 24 h was still 43% of preinfusion levels, indicating that the alternative pathway may account for almost half of the total bile acid synthesis (20). Precursor studies in humans indicate that the acidic pathway synthesizes ~50% of the total bile acids (14). In adult patients with liver diseases, when bile acid synthesis is reduced (54–57), concentrations of cholestenoic acids are elevated (58), which also suggests that the alternative pathway is a significant contributor to bile acid synthesis in humans.

Here, we describe an infant with severe neonatal cholestasis whose biological fluids were virtually devoid of 7α-hydroxylated bile acids due to a mutation in the gene encoding oxysterol 7α-hydroxylase. In addition to establishing a further inborn error in bile acid synthesis as a cause of cholestatic liver disease, these observations demonstrate the quantitative importance of the acidic pathway for bile acid synthesis in human fetal and neonatal life. The infant, a 10-wk-old Mexican offspring of a first cousin marriage presented with progressive jaundice, elevated concentrations of serum liver enzymes, and a prolonged prothrombin time due in part to vitamin K malabsorption. Interestingly, there was a normal serum γ-glutamyltranspeptidase concentration, which has been shown previously to be highly associated with, although not exclusive to, patients with inborn errors in bile acid synthesis (59), since it is also a feature of Byler’s disease, a condition of progressive familial intrahepatic cholestasis (60–62). A liver biopsy and histologic analysis revealed diffuse synchytial giant cell transformation of hepatocytes with associated bile ductule proliferation and fibrosis (Fig. 2) and the histologic appearance resembled that observed in other inborn errors in bile acid synthesis (3, 4, 11, 63).

The diagnosis of a specific defect in 7α-hydroxylation was established by FAB-MS analysis of the urine, which revealed a mass spectrum characterized by the absence of the normal primary bile acid conjugates and the presence of a series of unusual bile acids having molecular weights characteristic of unsaturated monohydroxylated bile acid conjugates. These were confirmed by GC-MS analysis to be monohydroxy bile acids with a 3β-hydroxy-Δ5 structure, and in common with most steroids with this nuclear structure, these metabolites are preferentially sulfated in the liver (64, 65). The 3β-hydroxy-Δ5 bile acids constituted >90% of the serum bile acids and >75% of the urinary bile acids. These metabolites also accounted for 24% of the liver tissue bile acids even during exogenous cholic acid therapy (Table I). 3β-Hydroxy-5-cholenoic acid is a normal constituent of amniotic fluid (66, 67) and meconium (68) and is found in small proportions in normal adult urine (32).

However, it is increased in the urine of infants with cholestatic liver disease (35, 69), although not to the extent observed in the patient reported here; furthermore, in contrast to our patient, high concentrations of cholic and chenodeoxycholic acids accompany the elevations in 3β-hydroxy-5-cholenoic acid. 3β-Hydroxy-5-cholenoic acid was also found in low concentrations in the urine, but not the serum of the parents, who both showed serum and urinary bile acid profiles that were similar to those of healthy adults.

The mechanism of liver injury in this patient is proposed to be due to the accumulation of high concentrations of hepato-
toxic monohydroxy bile acids with the \(3\beta\)-hydroxy-\(\Delta^5\) structure (70). The cholestatic effects of these metabolites would be further exacerbated by the lack of primary bile acids, which would normally provide the essential driving force for bile flow. It has been demonstrated that the taurine conjugate of the dihydroxy bile acid, \(3\beta,7a\)-dihydroxy-\(5\)-cholenoic acid, a major bile acid synthesized by patients with liver disease due to a deficiency in \(3\beta\)-hydroxy-\(C_{27}\)-steroid dehydrogenase/isomerase (3), is not transported in an ATP-dependent manner, and that it also inhibits the ATP-dependent transport of cholic acid across rat canalicular plasma membranes (71). The monohydroxy bile acid, tauro-\(3\beta\)-hydroxy-\(5\)-cholenoic acid, is markedly cholestatic in the rat, reducing bile flow and cholesteryl and phospholipid secretion in a dose-dependent manner (70, 72). It was shown to have an even greater cholestatic potency than its saturated analogue, taurolithocholic acid (72). The accumulation of monohydroxy bile acids may also injure the liver through the generation of oxidant stress (73). Contrary to the general assumption that sulfation of bile acids provides a protective mechanism against cholestasis, tauro-\(3\beta\)-hydroxy-\(5\)-cholenoate sulfate proved still to be markedly cholestatic in the rat, albeit with a less pronounced effect than that seen with the nonsulfated analogue (72). The accumulation of \(3\beta\)-hydroxy-\(\Delta^5\) cholenoic and cholestenolic acids in the liver of this patient could also contribute to reduced cholic acid synthesis via downregulation of the classical pathway using cholesteryl \(7a\)-hydroxylase. In this regard, infusion of \(3\beta\)-hydroxy-\(\Delta^5\)-cholenoic acid reduces cholic acid synthesis in the rabbit (74).

Analysis of neutral sterol fractions of serum and urine from the patient revealed GC profiles that featured a prominence of a major oxysterol, identified by mass spectrometry as 27-hydroxycholesterol; concentrations in serum (314 \(\mu\)g/ml or 781 \(\mu\)mol/liter) were found to be >4,500-fold those reported for the mean values in normal adult serum (39, 75–79). In addition, evidence for other side chain hydroxylated sterols was obtained by mass spectrometry, including elevated concentrations of 24-hydroxycholesterol, whereas \(7a\)-hydroxycholesterol could not be identified in any of the samples analyzed. The lack of \(7a\)-hydroxylated bile acids and sterols implies a deficiency in the activity of either cholesterol \(7a\)-hydroxylase or oxysterol \(7a\)-hydroxylase (Fig. 13) and the biochemical presentation is consistent with a metabolic defect involving the latter enzyme, since \(3\beta\)-hydroxy-\(5\)-cholenoic and \(3\beta\)-hydroxy-\(5\)-cholestenoic acids can only be formed via the acidic pathway (Fig. 13), neither being good substrates for cholesterol \(7a\)-hydroxylase or \(\Delta^5\)-cholenoic acid reductions in synthesis in the rabbit (74).

Oxysterol \(7a\)-Hydroxylase Deficiency
born errors in bile acid synthesis. Oral primary bile acid therapy, which has led to normalization in liver function and histology in most patients with liver disease due to deficiencies in 3β-hydroxy-C₂₇-steroid dehydrogenase/isomerase (3) and Δ⁵-3-oxosteroid 5β-reductase (4), proved ineffective in this patient. Cholic acid administration in the previously described bile acid defects downregulates endogenous bile acid synthesis, leading to a virtual disappearance of the atypical hepatotoxic metabolites concomitant with clinical improvement (1, 2, 11, 12). This biochemical response did not occur in this patient, consistent with a lack in 7α-hydroxylation activity and suggesting that cholic acid normally downregulates the expression of this gene (21). Consequently, it would appear that orthotopic liver transplantation may be the only therapeutic modality in the face of advancing liver disease due to hepatotoxicity from the transplantation may be the only therapeutic modality in the face of advancing liver disease due to hepatotoxicity from the transplanted liver.

Consequently, it would appear that orthotopic liver transplantation may be the only therapeutic modality in the face of advancing liver disease due to hepatotoxicity from the transplanted liver.

Acknowledgments

We thank S. Nair for assistance with tissue culture, and M.S. Brown, J.L. Goldstein, and H.H. Hobbs for comments.

This research was supported by grants from the National Organization for Rare Disorders (to K.D.R. Setchell), the National Institutes of Health (RO1DK38446 to R.J. Sokol, and HL20948 to D.W. Russell), the NIH National Centers for Research Resources (RR00609 to R.J. Sokol), the Deutsche Forschungsgemeinschaft (M. Schwarz), the Foundation BLANCEFLOR Boncompagni-Ludovisi, and the Centre for Genome Research (R. Lathe).

References


Oxysterol 7\( \alpha \)-Hydroxylase Deficiency 1703